

REVIEW

Open Access

Genome-wide association studies of severe *P. falciparum* malaria susceptibility: progress, pitfalls and prospects



Delesa Damena^{1*}, Awany Denis¹, Lemu Golassa² and Emile R. Chimusa¹

Abstract

Background: *P. falciparum* malaria has been recognized as one of the prominent evolutionary selective forces of human genome that led to the emergence of multiple host protective alleles. A comprehensive understanding of the genetic bases of severe malaria susceptibility and resistance can potentially pave ways to the development of new therapeutics and vaccines. Genome-wide association studies (GWASs) have recently been implemented in malaria endemic areas and identified a number of novel association genetic variants. However, there are several open questions around heritability, epistatic interactions, genetic correlations and associated molecular pathways among others. Here, we assess the progress and pitfalls of severe malaria susceptibility GWASs and discuss the biology of the novel variants.

Results: We obtained all severe malaria susceptibility GWASs published thus far and accessed GWAS dataset of Gambian populations from European Phenome Genome Archive (EGA) through the MalariaGen consortium standard data access protocols. We noticed that, while some of the well-known variants including *HbS* and *ABO* blood group were replicated across endemic populations, only few novel variants were convincingly identified and their biological functions remain to be understood. We estimated SNP-heritability of severe malaria at 20.1% in Gambian populations and showed how advanced statistical genetic analytic methods can potentially be implemented in malaria susceptibility studies to provide useful functional insights.

Conclusions: The ultimate goal of malaria susceptibility study is to discover a novel causal biological pathway that provide protections against severe malaria; a fundamental step towards translational medicine such as development of vaccine and new therapeutics. Beyond single locus analysis, the future direction of malaria susceptibility requires a paradigm shift from single -omics to multi-stage and multi-dimensional integrative functional studies that combines multiple data types from the human host, the parasite, the mosquitoes and the environment. The current biotechnological and statistical advances may eventually lead to the feasibility of systems biology studies and revolutionize malaria research.

Keywords: Genome-wide association study, *P. falciparum* malaria, Susceptibility, Resistance, Heritability, Pathways, Fine-mapping, Multi-omics, Systems biology

* Correspondence: damenadelesa@gmail.com

¹Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Private Bag, Rondebosch, Cape Town 7700, South Africa

Full list of author information is available at the end of the article



Background

Plasmodium falciparum, the causative agent of severe malaria, has been infecting humans for at least 5000–10,000 years following the advent and expansions of agriculture [1–3]. Malaria still poses a huge social, economic and health problems in several low-income countries, particularly in sub-Saharan Africa [4, 5]. *P. falciparum* infects millions and kills hundreds of thousands of African children each year. However, this constitutes only a small proportion (1%) of the populations in endemic areas in which the infections progress to severe malaria such as profound anemia or cerebral malaria [6, 7].

Comprehensive understanding of the genetic basis of resistance and susceptibility to severe malaria is crucial to understand the molecular mechanisms of host-parasite interactions that can inform the development of effective therapeutics, vaccination, diagnostics and risk prediction strategies [8, 9]. To this end, GWASs have recently been implemented in malaria endemic areas and replicated some of the well-known variants including *HbS* and *ABO* blood group [10–13]. Despite the fact that malaria is expected to drive several protective alleles to high frequencies that can be captured by GWAS approach, it is unclear why only limited number of novel variants were identified of which a small fraction was replicated across endemic populations. Some of the contributing factors for this discrepancy might include small sample sizes, the genetic diversity of the malaria endemic populations and allelic heterogeneity of malaria protective alleles among others. On the other hand, several association signals distributed across the genome that didn't pass GWAS significance threshold were observed in these studies [10–13]; suggesting the possible existence of polygenic effects. This raises several key questions including 1) What is the genetic architecture of malaria susceptibility/resistance? 2) What is the heritability of malaria susceptibility and its distribution across the genome? and 3) What is the extent and pattern of epistasis and pleiotropy at genome wide scale?

Here we review the current status of malaria susceptibility GWASs and provide guidance to future research directions. We begin by assessing the progress and pitfalls of severe malaria susceptibility GWASs and discuss the biology of the novel variants. We then provide an overview of the recent progresses in post-GWAS approaches and discuss how these methods can be implemented in severe malaria susceptibility studies to better understand the underlying biology. We conclude by discussing on research areas where further works are needed in light of the global malaria eradication efforts.

Results

Severe *P. falciparum* malaria susceptibility GWASs: progress and pitfalls

In malaria endemic areas where repeated *P. falciparum* infection is very common, the majority of children recover from malaria. However, a small proportion of

infections progress to the severe form of the disease such as severe anaemia, cerebral malaria, acidosis and respiratory distress [7]. Cerebral malaria is the commonest cause of death characterized by rapid onset of generalized convulsion followed by coma (a Blantyre coma score of less than 3 in the presence of *P. falciparum* parasitaemia). Severe anaemia is defined as a haematocrit of < 15% or haemoglobin < 5 g/dl in the presence of *P. falciparum* parasitaemia [14]. Although the clinical outcome of malaria is determined by several factors including infection rate, parasite genetics and the environment, the host-genetics factor contribute about 25% of *P. falciparum* malaria severity. However only small proportions (~ 2%) of heritability is explained by the well-known variants such as sickle-cell anaemia and α -thalassaemia [7]. The conventional approaches such as candidate gene-based studies [15–17] and the family based linkage studies [18, 19] have been implemented at least for the last three decades and identified several association variants. Unfortunately, the majority of the findings were discordant and failed to replicate in different populations [1].

GWAS in malaria susceptibility study was motivated to address the acute limitations of the conventional approaches and provide better understandings of the underpinning genetics at genome wide scale. To this effect, a global partnership of malaria researchers, named as Malaria Genomic Epidemiology Network (MalariaGEN) was established in 2008 [20]. MalariaGEN has successfully conducted multi-center-scale GWASs [10–13] and reported some interesting findings which we will discuss in later sections. However, the GWAS approach has several limitations including 1) weak performances in genetically diverse populations [8], lack of translation of associated loci into suitable biological hypotheses [21], 3) the well-known problem of missing heritability [22], 4) the lack of understanding of how multiple modestly associated loci within genes interact to influence a phenotype [23], 5) inefficiency in distinguishing between inflation from bias (cryptic relatedness and population stratification) and true signal from polygenicity [24], 6) the imperfection of asymptotic distribution of current mixed model association in the case of low-frequency variants [25]. The discussion on limitations of GWAS approach is beyond the scope of this review. Here we focus on the major challenges of malaria susceptibility GWASs and highlight the recent positive progresses.

Genetic diversity of African population

Owing to the fact that Africa is the origin of modern humans, there is high level of genetic diversity and weak linkage disequilibrium (LD) in Africans compared to non-African populations [26–28]. These distinct genetic characteristics created major setbacks to GWASs in

African populations primarily because of lack of representative dense genotype chips and reference panels [8]. It was estimated that a GWAS of 0.6 million SNPs based on HapMap phase 1 dataset in European population has an equivalent power to the chips with 1.5 million SNPs in African populations [29].

This might have affected the power of previous malaria GWASs. For instance, in the first malaria GWAS [10], *HbS* locus, a well-known variant conferring resistance to severe malaria demonstrated a weak signal (p-values $\sim 1 \times 10^{-7}$) because of the weak LD between causal variants and the SNPs that were genotyped. After which authors sequenced the locus, undertook multipoint imputation, used proper reference panel and dramatically improved the signal to p-value $\sim 1 \times 10^{-14}$. However, coverages of the genotyping chips have been enormously improved to be able to capture the genetic diversities among global populations following the recent technological advances and availability of diverse reference data sets [27, 30–32]. For instance, Omni microarrays based GWASs were proven to have considerable power in African populations [27].

Such developments have also facilitated imputation-based studies in African populations. For instance, Band et al. [9] showed the feasibility of multi-point imputation based meta-analysis in for malaria GWASs using HapMap3 haplotype panel. Another study showed a substantial improvement of imputation accuracy by using the more diversified AGVP WGS reference panel [27]. We believe that the reference dataset will grow further and accelerate genomic research by including wide range of haplotype diversity in African populations.

Sample size

In GWAS, a stringent p-value (0.5×10^{-8}) is usually needed to declare evidences of genuine associations to minimize false discovery rate that can arise from multiple testing [33]. Thus, very large sample size is required to achieve genome-wide significance threshold particularly for loci with modest effect sizes. The required sample size is even much higher for studies in population of African ancestry because of the higher genetic diversity. In contrast, the current sample sizes of GWASs in African populations including those of malaria susceptibility are generally small compared to non-Africans [34] which might have affected the power of the studies. Therefore, more powered studies in African population might lead to the discovery of novel association variants.

Allelic heterogeneity of malaria protective variants

Allelic heterogeneity defined as the presence of multiple causal variants in the same locus is one of the challenges of GWA and fine mapping studies [35]. The presence of multiple causal variants with variable effect sizes and LD

structures limits the power of GWASs. In such cases, fine-mapping methods will also have lower accuracy to pinpoint true causal variants among several possible candidates [35]. Allelic heterogeneity has been described for the well-known loci affecting malaria susceptibility, which is reflected by their geographical distribution within malaria-endemic regions [36].

Several distinct variants are known to exist at the loci causing inherited hemoglobinopathies [36]. Allele frequencies, LD structure and effect sizes of these variants differ in sub-populations within endemic areas [37]. For instance, the sickle cell allele, *HbS*, is known to have different haplotype structure and effect sizes in different regions of sub-Saharan Africa [27]. *HbC* allele is common in some parts of west Africa such as Burkina Faso, Ghana, Togo and Benin while absent in other west African countries such as Cameroon and Chad [38]. In the same region, several alternative alleles with differing effect sizes are known to exist at the locus causing G6PD deficiency [36, 39]. Although population specific studies can minimize such challenges, the current MalariaGEN datasets are comprised of several populations each with small sample size; making it difficult to undertake powered GWASs for specific geographic areas.

Genetic architecture of malaria susceptibility and resistance

The performance of GWASs is dependent on the genetic architecture of the diseases and traits under investigation. For the majority of complex diseases and traits, the GWAS variants identified thus far, only explain a very small proportion of heritability; a phenomenon commonly termed as ‘missing’ heritability [22]. There have been different explanations for the ‘missing’ heritability including common disease rare variant hypothesis [40], none-additive components, primary epistasis [41, 42] and polygenic genetic architecture [21].

One of the challenges of malaria GWASs is that we don't know much about the genetic architecture of malaria protection trait. First, as one of the prominent evolutionary selective forces, the majority of malaria protective alleles might have evolved under positive selection and might potentially be balanced by other forces [43]. In this case, the protective variants are expected to have large effect sizes with high allele frequencies that can be detected by the conventional GWAS approaches; provided that proper reference panel and genotyping platforms are used [43]. Second, similar to the genetic architecture of other infectious diseases [44], malaria protection trait might largely be attributed to few rare variants of large effect sizes. In this case, the GWASs are underpowered as rare variants might not be in LD with common variants. Third, malaria protection trait might be mainly under polygenic and epistatic control [1, 7,

45] which the conventional GWAS approach can't capture.

Biology of the novel variants identified by severe *P. falciparum* malaria GWASs

Severe malaria GWASs have replicated some of the well-known variants such as *HbS* and *ABO* blood groups and few novel variants related to red blood cell membrane biology which reinforce the importance of erythrocyte variants for protection against severe malaria. Besides, the GWASs have identified notable novel association variants in immune and other pathways that may directly or indirectly influence the disease outcome. The epidemiology and biology of the well-known variants were reviewed else-where [1]. Below we characterize the novel malaria susceptibility genetic variants identified by GWASs. We first discuss the biology of two variants such as cluster of the *glycophorin genes* (*GYPA/B/E*) and *ATP2B4* that were well-replicated across malaria endemic populations. We then extend our discussion to other novel variants.

ATP2B4

The association of variants in *ATP2B4* gene with severe malaria susceptibility was reported by Timmann et al. [11] in Ghanaian populations and replicated in subsequent studies in other populations [12, 46]. SNPs in this locus were also linked with reduction of mean corpuscular hemoglobin concentration (MCHC) level [47]. *ATP2B4* encodes a ubiquitous plasma membrane calcium-transporting protein (*PMCA4b*) [48]. *PMCA4b* is widely expressed in different tissues and is the main transporter of Ca^{2+} in erythrocyte membrane [48].

A recent study showed that the GWAS SNPs are localized in a previously unrecognized *ATP2B4* haplotype named as 'haplotype-1' and individuals with this haplotype exhibit a reduced *PMCA4b* expression level [49]. In this study, it was also shown that the reduction of *PMCA4b* expression significantly decreases the calcium extrusion in RBCs. Consistent with this, a study conducted by Lessard et al. and colleagues elegantly characterized the *ATP2B4* locus using a combination of transcriptomic, epigenomic and gene-editing study approaches [50]. The authors first undertook knock out experiment and demonstrated that *ATP2B4* knocked-out mice express an elevated level of MCHC. Then, they conducted expression quantitative trait locus (eQTL) mapping studies using UK biobank dataset and showed strong associations between *ATP2B4* erythroblast specific variants and RBC related traits including MCHC level, decreased RBC distribution and increased hemoglobin levels.

Further analysis of DNase I hypersensitivity sites (DHSs) at *ATP2B4* and eQTL mapping showed that the GWAS SNPs are mapped to an erythroid specific enhancer element. Deletion of this enhancer from human erythroid cell line using CRISPR-Cas9 system showed a dose dependent reduction of *ATP2B4* expression level. Bi-allelic deletion of the enhancer resulted in eighty three percent reduction of *ATP2B4* expression level compared to the wild type while mono-allelic deletion resulted in moderate reduction of the *ATP2B4* expression level [50].

To determine the effects of the regulatory variants at *ATP2B4* gene on calcium homeostasis, Lessard et al. measured the calcium concentration in unedited and edited (*ATP2B4* enhancer deleted) HUDEP-2 cells. The edited cells demonstrated higher intracellular calcium level compared to wild cells indicating that *ATP2B4* expression is essential for plasma membrane calcium pump. The disturbance of intracellular Ca^{2+} homeostasis might play an important role in impairing the invasion, development and reproduction of malaria parasite in RBCs [51, 52]. Therefore, *ATP2B4* region can potentially be targeted for development of vaccine and therapeutics.

Cluster of the 3 *glycophorin genes* (*GYPA/B/E*)

The largest multi-center malaria susceptibility GWAS which included eleven populations was conducted by Band et al. [12]. In this study, 34 genomic regions containing potential susceptibility loci for severe malaria were identified. Among which, a strong signal was observed at locus between *FREM3* gene and cluster of 3 *glycophorin genes* (*GYPA/B/E*) on Chromosome 4. A haplotype (at SNP *rs184895969*) within this region was reported to reduce the risk of developing severe malaria by about 40% and is common in Kenyan populations with allele frequency reaching 10% [12].

A subsequent study in the same populations identified a large number of copy number variants which are characterized by deletion, duplications and hybrid structures in *GYPA* and *GYPB* genes [53]. Of which a distinct variant called *DUP4* was reported to reduce the risk of severe malaria by about 40% in eastern African (Kenya) populations. Further characterization showed that, this variant is composed of complex *GYPB-A* hybrid and encode *Dantu* antigen in MNS blood group system [53]. The association of this region with severe malaria was supported by another recent case control study in Tanzanian populations [54]. The glycophorin gene cluster, *GYPA* and *GYPB* encode the MNS blood group system and are known to be receptors for *P. falciparum* during RBC invasion [55]. *GYPA* and *GYPB* serve as an erythrocyte membrane receptor for *EBA-175* and *EBL-1* proteins of the parasite respectively [56]. This genomic region is also known to be under an ancient selective

pressure resulted from host-pathogen arm races between *P.falciparum* and humans [57]. Further functional analysis is required to better understand how these variants affect the invasion and/or development of the parasites in erythrocytes and convey protection against severe malaria.

SCO1 and DDC

Notable association signals were identified by the first malaria susceptibility GWAS conducted in Gambian population [10]. The first lead SNP (*rs6503319*) is located close to *SCO1* (*synthesis of cytochrome c oxidase*) gene on chromosome 17p13. *SCO1* is a multi-functional signaling protein which plays an essential role in *mitochondrial cytochrome c oxidase (COX)* copper delivery pathways [58]. *COX* catalyzes electron transfer from reduced cytochrome c to oxygen and is abundantly expressed in muscles, brain and liver [58]. Deficiency of *COX* caused by mutations in *SCO1* gene can lead to respiratory distress and severe metabolic acidosis [59] which are also the major complications during cerebral malaria [60]. Further studies are needed to understand how the variants in *SCO1* gene are associated with the pathological pathways of cerebral malaria.

The second notable association signal identified in this study was *Dihydroxyphenyl-alanine decarboxylase (DDC)* on Chromosome 7p12.2. A recent study in Tanzanian populations replicated the association of *DDC* variants with cerebral malaria [54]. *DDC* gene encodes *Aromatic-L-amino-acid decarboxylase* enzyme which is involved in biosynthesis of neurotransmitters such as dopamine and serotonin [61]. *DDC* is an essential enzyme for brain and nervous developments and its deficiency is associated with reduced cognitive functions [61]. *DDC* is involved in cellular immunity and contributes in protection against parasitic disease in invertebrates [62]. Furthermore, mutations in *DDC* gene was reported to be associated with refractoriness of *Anopheles gambiae* mosquito against *P.falciparum* parasites [63]

MARVELD3

In addition to the *ATP2B4*, Timmann et al. [11] identified an association SNP (*rs2334880*) on chromosome 16p 22.2 which is linked to *MARVELD3*. However, this association has not been replicated in other studies. *MARVELD3* is one of the components of tight junction proteins in several epithelial and endothelial tissues and is expressed as two alternative spliced variants [64]. These proteins are involved in assembly, development, maintenances and regulations of tight junction. Tight junctions play a major role in intracellular adhesions and involved in sub-cellular signaling mechanisms [64].

IL-12 receptors and IL-23 receptors

The most recent malaria susceptibility GWAS was conducted in Tanzanian population [13]. In this study, notable associations signals were identified in immune pathways including in interleukin receptors (*IL-23R* and *IL-12RBR2*), *in ketch-like proteins (KLHL3)* and Human Leucocyte Antigen (HLA) regions. *Interleukin-12* is formed from a heterodimer of *IL12B (ILp40 subunit)* and *IL-12A (ILp35 subunit)* [65]. *IL-12* plays a vital role in stimulating cell-mediated immune responses against intra-cellular pathogens through binding to high affinity *IL-12RBI* and *IL-12RBR2* receptor complexes. It promotes the development of *T-helper cells (Th1)* and enhances the production of *INF-γ*, both of which are known to mediate the clearance of intracellular pathogens [65]. In malaria, *IL-12* has been implicated in mediating the protective immunity both in experimental animals and in humans [66]. *IL-23* is an important pro-inflammatory cytokine that shares p40 subunits with *IL12* [67]. It induces the differentiation of naive *CD4 T*-cells to *IL-17* which plays key roles in pathogenesis of autoimmune diseases [68].

HLA is encoded by the Major Histocompatibility Complex (MHC), the most polymorphic genes known in human genome. The diversity of MHC is believed to be driven by selection pressure from infectious pathogens and known to be associated with the risk of several infectious diseases [69]. HLA variants such as HLA class I antigen (*HLA-Bw53*) and HLA class II variant (*DRB1*1302-DQB1*0501*) were reported to confer protections against severe malaria in Gambian populations [69]. HLA class I antigen is expressed by liver cells suggesting that T cells (CTL) responses might efficiently act against the liver stage of malaria parasite in individuals with *HLA-Bw53* [69]. On the other hand, individuals with *DRB1*1302-DQB1*0501* variant might possess efficient antigen presentation mechanism that can lead to rapid clearance of blood stage parasites [69].

Variants in immune pathways are of great interest because of their potential to inform the development of effective malaria vaccines [1]. The current study is interesting in that several putative variants in immune pathways were identified. However, the power of this study is limited because of relatively smaller sample size and weak significance threshold used to interpret the findings. Therefore, further studies with higher detective power are needed to consolidate the findings (Table 1).

Polygenic genetic architecture and epistasis: Presenting the absent in the current severe malaria GWASs

Polygenic genetic architecture

Polygenic view of genetic architecture is gaining ground in genetic epidemiological studies and widely implicated for the 'missing' of heritability in GWAS analysis [70].

Table 1 Summary of the novel severe malaria susceptibility and resistance association variants identified by GWASs

Genomic regions containing the association variants					Genome-wide association studies							
Nearest gene name	Chr	Position	SNP ID (Ref/Alt)	MOI	Jallow et al. [10] Pop: Gambian N = 2560 (case =1060, control = 1500)		Timmann et al. [11] Pop: Ghanaian N = 2153 (case =1325, control =828)		Band et al. [12] Pop: African (11 countries) N = 11,552 (case = 5633, control = 5919)		Ravenhall et al. [13] Pop: Tanzanian N = 914 case =449, control = 465)	
					OR	p-value	OR	P-value	OR	P-value	OR	P-value
ATP2B4	01	203658471	rs 4951377 (A/G)	DO	-	-	-	-	-	3.1x10 ⁻⁹	-	-
		203654024	rs 10900585(T/G)	AD	-	-	0.61	1.9 x 10 ⁻¹⁰	-	-	-	-
		203660781	rs4951074(G/A)	AD	-	-	0.62	1.3 x 10 ⁻⁹	-	-	-	-
IL23R, IL12RB	01	67,731,614	rs6682413(-)	RE	-	-	-	-	-	-	0.48	8 x 10 ⁻⁷
GYP A/B/E and FREM3	04	143777125	rs184895969(A/C)	DO	-	-	-	-	0.67	9.5 x 10 ⁻¹¹	-	-
C4orf17	04	100429757	rs73832816(-)	REC	-	-	-	-	-	-	0.29	3.8 x 10 ⁻⁷
AF146191.4-004 (lincRNA)	04	90717704	rs114169033(-)	AD	-	-	-	-	-	-	3.32	6.7 x 10 ⁻⁷
AC108142.1 (antisense)	04	82822332	rs1878468	HET	-	-	-	-	-	-	0.383	9.0 x 10 ⁻⁷
Intergenic	05	43,909,343	rs113449872(-)	HET	-	-	-	-	-	-	0.35	2.2 x 10 ⁻⁸
KLHL3, MYOT	05	37,011,761	rs2967790(-)	AD	-	-	-	-	-	-	0.60	5.9 x 10 ⁻⁷
TREML4	06	41,205,690	rs9296359 (-)	HET	-	-	-	-	-	-	4.08	1.2 x 10 ⁻⁷
DDC	07	50,623,201	rs10249420(C/G)	AD	0.69	6.8 x 10 ⁻⁵	-	-	-	-	-	-
			rs1451375(-)	DO	0.75	6.1x10 ⁻⁶	-	-	-	-	-	-
Intergenic	07	53,676,837	rs17624383(-)	AD	-	-	-	-	-	-	-	5.6 x 10 ⁻⁷
CSMD1	08	4754838	rs73505850(-)	AD	-	-	-	-	-	-	4.79	5.9 x 10 ⁻⁷
LINC00944	12	127237620	rs11335470 (-)	HET	-	-	-	-	-	-	0.40	2.5 x 10 ⁻⁷
Intergenic	11	130,417,522	rs3133394	AD	-	-	-	-	-	-	0.5	9.4x10 ⁻⁷
FAM155A	13	108228013	rs144312179(-)	AD	-	-	-	-	-	-	0.2	6.2 x 10 ⁻⁷
MARVELD3	16	71,653,637	rs2334880 (T/C)	AD	-	-	1.19	1.9 x 10 ⁻⁶	-	-	-	-
SOC1	17	10,573,909	rs65033119(-)	AD	1.21	7.2 x 10 ⁻⁷	-	-	-	-	-	-
Intergenic (LINC00670)	17	12,399,526	rs149085856(-)	AD	-	-	-	-	-	-	3.87	2.1x10 ⁻⁷
ZNF536	19	1,069,639	rs8109875(-)	REC	-	-	-	-	-	-	0.5	5.7 x 10 ⁻⁷

MIO Mode of inheritance, AD Additive, HET Heterozygous, DO Dominant, REC Recessive, OR Odd-ratio, Ref Reference allele, Alt Alternative allele, Pop Population

The rationale behind polygenic inheritance is that complex-traits/diseases are influenced by multiple variants with modest effects that are too small to pass the stringent genome wide significance threshold [71]. In standard GWAS analysis, ‘Genomic control’ (GC) method is applied as a quality-control measure to minimize spurious associations that can be caused by population structures such as population stratification and cryptic relatedness.

However, a slight inflation of the test statistics (true but weak signals) which cannot be corrected by GC was initially observed across the genome in a Schizophrenia GWAS [72]. Subsequently, this observation has been supported by other studies [73] and led to the development of a number of statistical tools aiming to capture polygenic signals at genome-wide scale including 1) polygenic scoring method implemented in PLINK software [74] ; 2)

Mixed Linear Models (MLM) such as: GCTA [73], BOLT-LMM [75] , Bayes-R [76] and LDAK [77, 78], PCGC [79] 3) linkage-disequilibrium (LD) score regression method [80] among others.

Polygenic contributions in malaria susceptibility and resistance

Co-evolution of host-pathogen model predicts that multiple host loci are involved in resistance/susceptibility to infectious diseases due to the complex interactions between the multi-locus parasite genotype and the corresponding defense from the host-genome [42, 81]. Indeed, malaria might have left multiple genetic variants; the majority of which have effects too small to be detected by the standard GWASs. The existence of polygenic inheritance in malaria protection was predicted by several authors

[1, 7] and supported by the GWASs. For instance, the largest malaria susceptibility GWAS so far, identified 34 regions of the genome containing variants with evidence of associations [12]. Earlier GWAS in Ghanaian population identified 40 genomic regions containing 102 SNPs with evidences of association in the discovery phase of the study [11]. The recent GWAS in Tanzanian populations [13] identified 2322 SNPs at several regions across the genome.

Thus, implementation of polygenic analytic methods in malaria studies may potentially shed more light to the underlying biology. For instance, heritability can be estimated and partitioned in to different cell-types and functional groups and molecular pathways which enable to localize causal variants. Furthermore, these approaches can be extended to explore the genetic correlations between susceptibility to malaria and susceptibility to other infectious diseases. The existence of shared genetic basis between infectious diseases susceptibility/protection is well-documented [82]. However, the extent and pattern of these correlations have not been systematically investigated at genome-wide scale; partly because of inadequate GWAS data for infectious diseases. Such studies can potentially provide clues to common molecular processes between resistance/susceptibility to infectious diseases that will have practical importance including designing multi-purpose vaccine and genetic risk prediction strategies.

Heritability of severe malaria in Gambian population

To figure out how polygenic analysis can be implemented in malaria susceptibility, we accessed the Gambian malaria susceptibility GWAS dataset from European Phenome Genome Archive (EGA) through data application procedure and estimated heritability of malaria susceptibility using MLM approaches. The Gambian GWAS data is the largest MalariaGen dataset obtained from a single

country comprised of 4920 samples (2429 cases and 2491controls) and 1.6 million SNPs that passed GWAS quality control (QC). We first excluded the known malaria susceptibility associated loci and performed stepwise extra QC filtering. Specifically, we focused on sample relatedness, SNP missingness proportion and SNP differential missing proportion which are well-known to affect the accuracy of heritability estimation [78]. We then estimated the heritability using GCTA model for different QC thresholds by including 10 principal components (PCs) as fixed effects to account for population structure. As expected, the estimation was unstable when less stringent QC thresholds is applied (varying from 37.8 to 20.1%) as shown in Table 2. However, when more stringent QC (Relatedness threshold (5%), SNP differential missingness proportion ($p \leq 1 \times 10^{-3}$) and SNPs missing proportion of ($p > 0.02$)) was applied, the estimation became stable (~ 20.1%, SE = .05). Neither the inclusion of more PCs (15, 20) as fixed effects nor SNP phasing further brought down the estimate. Using the same stringent QC threshold, the estimation was approximately the same for Mandinka ethnic group (~ 24.3%, SE = 0.6). We couldn't estimate for other ethnic groups because of smaller sample sizes. Furthermore, the use of PCGC model which is designed for case/control approximately showed the same estimate (19.8%, SE = .07).

Although our heritability estimation is fairly stable when stringent QC is implemented, care should be taken in interpreting these results: First, all polygenic methods perform better in less structured data obtained from homogenous populations than the MalariaGen dataset which is comprised of diverse populations spanning most of the Malaria endemic belt in Africa. Second, the methods are designed and perform well in highly polygenic traits/diseases in which effects of each variant is

Table 2 SNP-heritability of severe malaria susceptibility/resistance in Gambian population at different basic quality threshold using MLM

Population	Sample relatedness-threshold	SNP missingness-proportion	SNP differential-missingness Proportion	Prevalence	Covariate principal-components	No. Samples	No. SNPs	GCTA h2(% SE)	PCGC h2(SE)
Gambia	-	5%	-	1%	10	4920	1627656	37.8(.05).	
	5%	5%	1×10^{-10}	1%	10	4128	1627656	30.5(.05)	
	5%	5%	1×10^{-5}	1%	10	4128	1607610	28.7(.05)	
	5%	5%	1×10^{-3}	1%	10	4128	1570344	25.1(.05)	
	5%	2%	1×10^{-3}	1%	10	4128	1486554	20.1(.05)	19.8(.07)
	5%	2%	1×10^{-3}	1%	15	4128	1486554	22.5(.05)	
	5%	2%	1×10^{-3}	1%	20	4128	1486554	19.5(.05)	
	Phased	-	-	1%	10	4128	1627656	20.4(.06)	
Mandinka	5%	2%	1×10^{-3}	1%	10	1281	1486554	24.2(0.6)	

GCTA Genome Complex Trait Analysis, PCGC Phenotype Correlation Genotype Correlation regression

mostly modest. In contrast, a considerable proportion of malaria protection trait might be attributed to rare variants of large effect sizes that might not be in LD with common variants and can't not be 'tagged' by SNPs chip which means that the contributions of such variants will not be accounted for. Third, subtle population structure that cannot be corrected by conventional methods such as unmatched case/control can potentially create systematic biases to the estimates.

Epistasis

Epistasis is becoming one of the hot research topics in genetic epidemiological studies in the last few years because of the fact that none additive genetic variations are shown to have significant influence on the phenotype of complex traits/diseases than previously expected [83]. The available statistical approaches and software packages for detection of epistasis at genome-wide scale were reviewed elsewhere [83, 84]. These approaches have been applied in genetic studies of complex diseases such as lupus erythematosus [85], ankylosing spondylitis [86], psoriasis [87] and unraveled previously unknown epistasis interactions between risk loci which explained a significant proportion of 'missing' heritability of the respective diseases.

Epistasis between malaria risk loci have been well documented and implicated as one of the possible reasons for lack of replication of susceptibility variants in different populations and the 'missing' heritability. For instance, sickle-cell trait (*HbS*) and α *thalassaemia* were shown to demonstrate negative epistatic interactions such that the protection against severe malaria offered by *HbS* is reduced when co-inherited with α^+ *thalassaemia* [88].

A case-control study in Kenyan population also reported that α^+ *thalassaemia* modulates the effects of Haptoglobin (*Hp*) variants in predicting the risk of severe malaria [89]. In this study, it was shown that the combination of α^+ *thalassaemia* and *Hp2-1* variant synergistically increase the protection against severe malaria by about 37%. However, the protective effect is decreased to 13% when α^+ *thalassaemia* is inherited with *Hp1-1* and further diminished to neutral (zero) when inherited with *Hp2-2*. Similarly, in a multi-center case control study, the existence of negative epistasis interaction between *HbC* and *ATP2B* alleles was reported [15].

Another recent case control study of severe malaria in Kenya reported the existence of negative epistasis between a complement receptor called *S12* and α^+ *thalassaemia* in which the protective effect of *S12* higher in children with normal α -globin [90]. The extent and pattern of epistatic interaction at genome-wide scale is yet to be explored. In malaria susceptibility GWAS, the priority has been given to a single

locus analysis to identify novel risk loci. We expect that, the next step of malaria susceptibility GWAS will include the investigations of epistasis at genome-wide scale.

From GWAS to biology: multi-step and multi-dimensional analyses

Fine-mapping and pathway analyses

The ultimate goal of genetic susceptibility studies is to identify causal variants and understand the underlying biological pathways which can lead to translated medicine such as effective vaccines and therapeutics. However, translating GWAS signals in to biological themes remains an open problem because of the confounding effects from LD between association SNPs, limited knowledge of gene functions and localization of the majority of GWAS hits in non protein coding regulatory regions (regulatory SNPs) [91–93]. In attempt to address this challenge, several fine mapping strategies have been developed and implemented [94]. One such strategy is trans-ethnic fine mapping in which the natural variability of haplotype structure across ethnically diverse populations is used to narrow down candidate causative variants [95]. The smaller LD and diversity of haplotype structure in African population makes it relatively easier to identify the causal SNPs and target gene/genes through fine mapping approaches [8]. However, the fact that malaria protective alleles are heterogeneous across populations might challenge the application of trans-ethnic fine-mapping approaches in malaria susceptibility studies.

Alternatively, several fine mapping statistical tools have recently been developed following the advances in annotation data bases and improved reference panels. These include Bayesian approach, heuristic approach and penalized regression methods [96]. The principles, applications, strength and weakness of these methods is reviewed elsewhere [94, 96]. These methods are increasingly playing crucial role in the efforts being made to pinpoint causal variants of complex diseases/traits. For instance, Galarneau et al. [97] identified novel independent association signals by fine-mapping three loci that are known to influence fetal hemoglobin (HbF) levels. The authors sequenced the three loci (*BCL11A*, β -globin and *HBS1L-MYB*), undertook dense genotyping, performed step-wise conditional analysis and revealed previously un-recognized SNPs that explain additional genetic variation. Similarly, a recent fine mapping study of HLA region identified several susceptibility loci for multiple infectious diseases [82]. More sophisticated studies that combine statistical and functional fine-mapping strategies have recently been implemented and provided mechanistic insights to the genetic basis of complex diseases [98].

In addition to fine mapping approaches, pathway and interaction analysis can be another avenue for exploring molecular basis of Malaria susceptibility/resistance. Instead of emphasizing on single-variant analysis, these approaches test the coordinated effects of several variants at systems level using biological information from annotation data basis [99]. Pathway analysis improve study power by integrating cumulative effects of weak association signals and provide functional information by identifying associated sets of genes/proteins [100]. By implementing the pathway analysis approaches, several studies have gained new insights in understanding the genetic basis of complex diseases [101–103]. The available statistical tools for pathway and interaction analysis is reviewed in [104]. We therefore, advocate for the implementation of fine mapping and pathway analytic methods in malaria susceptibility studies to shed more light in to the underlying biology.

Epigenomics and Epigenome wide association studies

Epigenetics refers to heritable phenotype changes that do not involve alterations in the DNA sequences such as methylation, post-translational histone modification, histone variation, chromatin remodelling and non-coding RNAs [105]. Epigenetic impacts have recently been implicated in malaria susceptibility and resistance [106, 107]. For instance, in a recent study, strong transcriptional response was detected in monocytes of *P. falciparum* infected individuals from Fulani, an ethnic group that is less susceptible to malaria [107]. The authors suggested that, this response is likely regulated by genome wide chromatin alterations. The discussion on the possible mechanisms of epigenetic impacts on malaria susceptibility and resistance is beyond the scope of this paper and is reviewed in [108].

However, the majorities of epigenetic studies including those of malaria susceptibility and resistance have been limited to either small sample sizes or inadequate genome coverage and thus, lack adequate power to decipher the epigenetic impacts on complex diseases [105]. In effort to address this challenge, investigators recently developed a large-scale, systematic epigenomic equivalents of GWAS called epigenome-wide association studies (EWAS) that attempts to uncover epigenetic variants underlying common diseases/phenotype using genome-wide technologies such as Illumina 450 K array [109]. EWA approach recently gains a considerable attention partly due to the fact that the majorities of the GWAS SNPs are mapped to non coding regions of the genome implying that the variant SNPs cause changes in gene expression levels rather than causing changes in protein function [109]. Thus, combining both genetic (GWA) and epigenetic (EWA) approaches in parallel may prove a fruitful approach for understanding mechanisms of disease risk [109]. Undoubtedly, application of such

approaches may shed new light into mechanisms of malaria susceptibility and protection.

Multi-omics approaches

Today, there are significant advances in high throughput technologies that can generate big ‘-omic’ data from all spectrum of molecular biology [91]. The ‘-omics’ studies (Genomics, Epigenomics, Transcriptomics, Proteomics, Metabolomics) are crucial to understand the underpinning biology of complex diseases. In severe malaria, ‘-omics’ studies have provided important clues about the molecular events that lead to either complications or recovery from diseases. For instance, following the discovery of glycoprotein regions by the GWAS, a whole genome sequencing-based study [53] was conducted to characterize variants in this region and identified a novel distinct copy number variant called *DUP4* which reduces the risk of severe malaria by about 33%. In addition to this, a genome-wide gene expression study was conducted in Kenyan children and reported increased expression of genes related to neutrophil activation during malaria infections [110]. The authors also observed differential expression of heme- and erythrocyte-related genes in acute malaria patients which reaffirms the importance of erythrocyte-related genes in malaria susceptibility and resistance.

In another host-parasite interaction study, the importance of miRNA in inhibiting parasite growth in erythrocyte was reported [111]. The authors observed translocation of several host RBC miRNAs into *P. falciparum* parasites, as well as fusion of these human miRNAs with parasite mRNA transcripts to inhibit the translation of enzymes that are vital for the parasite development. Specifically, two micro-RNAs, miRNA-451 and let-7i, were highly enriched in *HbAS* and *HbSS* erythrocytes and these miRNAs along with miR-223 were shown to attenuate the growth of parasite [111].

However, ‘-omics’ studies are limited to single data-type analysis and lack adequate power to explain the complexity of molecular processes and usually lead to identification of correlations than causations [112]. Thus, integrating and analysing multiple ‘-omics’ data enables better understanding of the molecular processes and interactions that give rise to complex diseases/traits. For example, leveraging host microbiome relative abundance data as a second (quantitative) trait, and performing a joint analysis of bivariate phenotypes can increase statistical power by maximizing phenotypic information and inform how the interaction between host genotype with microbiome impacts the phenotype.

Multi-omics approaches aim to integrate big ‘-omics’ data, undertake ‘multi-step’ and ‘multidimensional’ analysis for elucidating complex biological problems [112]. Driven by the massive abundance of ‘-omics’ data from

wide ranges of biological molecules, multi-omics strategy have recently provided unprecedented successes in complex diseases/trait studies. The current state of art of multi-omics approach and available statistical methods is recently reviewed in Hasin et al. [112]

Malaria susceptibility and resistance is influenced by several host, parasite and environmental factors as depicted in Fig. 1. The protective alleles have independently evolved in different populations being shaped by the co-evolution and interaction between the human genome, the parasite and the environment [1]. Thus far, single ‘-omics’ data analysis enabled us to understand some of the factors that are associated with the malaria protective traits. To progress beyond associations and pinpoint the causal pathways, it may require to implement carefully designed, coordinated multi-omics studies that involve human host, the parasite, the environment and possibly mosquito. The current advents of high-throughput technologies in generating massive ‘-omics’ data and their continuously decreasing cost complemented with the availability of statistical tools which able to simultaneously capture millions of data points will lead to the

implementations of multi-omics approaches in malaria susceptibility studies.

Conclusions and perspectives

The ultimate goal of malaria susceptibility study is to discover a novel causal biological pathway that provide protections against severe malaria; a fundamental step towards translational medicine such as development of vaccine and new therapeutics that can facilitate the global malaria eradication efforts. To achieve this goal, various study approaches have been implemented at least for the last three decades and successfully identified several association variants.

Recently, a number of GWASs have been implemented in malaria endemic areas to better understand the underlying biology. While some of the well-known variants were replicated, only few novel variants were convincingly identified and their biological functions remains to be understood. Several limiting factors including genetic diversity of population in malaria endemic areas, allelic heterogeneity of protective variants, small sample sizes, lack of proper reference panel and




Fig. 1 Schematic representation of the integrative analyses. Systems biology approach which incorporate multiple layers of information from host (multi-omics), the environment and parasite genetic factors can potentially lead to the discovery of malaria protective pathways

proper genotyping chips might have negatively impacted the malaria GWASs.

Another challenge is that we don't know much about the genetic architecture of malaria protective trait. There are at least two scenarios in which GWAS approach might fail; First, malaria protective trait might largely be attributed to rare variants of large effect sizes that might not be in LD with common variants and can't be captured by the GWAS approach. Second, malaria might have left multiple genetic variants distributed across human genome; the majority of which have effects too small to be detected by the standard GWASs [1, 7]. Theoretically, the large sample sizes, dense genotyping chips or whole genome sequencing, use of appropriate reference panels and effective genotype imputation can address the majority of the challenges. However, given the resource constraints; especially, in Africa where malaria problem is the greatest, this will likely take several years to achieve.

On the other hand, the recent advances in statistical techniques is enabling to extract useful information from the present-day GWAS sample sizes. For example, a number of statistical approaches have been developed to capture polygenicity in complex diseases. We showed how these methods can potentially be implemented in malaria susceptibility studies and provide useful insights. We believe that further studies with larger sample sizes can elucidate the polygenic effects in malaria protective trait by extending the analysis to genome partitioning, risk prediction and genetic correlations.

Beyond single locus analysis, multi-step and multi-locus analyses including pathway analysis, fine mapping and interaction analysis can potentially be implemented in malaria susceptibility GWASs to gain new insights to the underpinning biology. For instance, pathway analysis can provide important information by analyzing the coordinated effects of several variants at systems level using biological information from annotation databases. Methods that combine statistical and functional fine-mapping strategies can potentially be implemented to pinpoint the causal variants from the GWAS association signals.

Most importantly, the future direction of malaria susceptibility requires a paradigm shift from single '-omics' to multi-stage and multi-dimensional integrative functional studies that combines multiple data types from the human host, the parasite, the mosquitoes and the environment. The current biotechnological advances, an ever-increasing annotation data bases and availability of advanced analytical techniques, will eventually lead to feasibility of systems biology studies and revolutionize malaria research.

Abbreviations

eQTL: Expression quantitative trait locus; EWAS: Epigenome wide association studies; GWAS: Genome wide association study; MLM: Mixed Linear Model

Acknowledgements

We thank Kwiatkowski's group from University of Oxford for their constructive comments and assistance. We thank Kirk Rokett and Ellen Leffler for their useful comments. We are very grateful to Gavin Band for his supervision and guidance in heritability analysis and his critical comments. I thank Newton's fund student transfer scheme for funding me during my stay at University of Oxford. We also thank Abdoulaye Djimde for his follow up.

Authors' contributions

DD conceived the work, designed and drafted the manuscript; LG and AD revised the manuscript; EC conceived the work, revised the manuscript and supervised the work. All authors read and approved the final manuscript.

Funding

DD is a PhD student funded by DELTAS Africa Initiative [grant 107740/Z/15/Z]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant 107740/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

Availability of data and materials

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Division of Human Genetics, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Private Bag, Rondebosch, Cape Town 7700, South Africa. ²Akilu Lema Institute of Pathobiology, Addis Ababa University, PO box 1176, Addis Ababa, Ethiopia.

Received: 8 December 2018 Accepted: 29 July 2019

Published online: 14 August 2019

References

- Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. *Am J Hum Genet.* 2005;77: 171–92. <https://doi.org/10.1086/432519>.
- Parikh S, Rosenthal PJ. Human genetics and malaria : relevance for the design of clinical trials. *J Infect Dis.* 2008;198:1255–7.
- Sabeti P, Usen S, Farhadian S, Jallow M, Doherty T, Newport M, et al. CD40L association with protection from severe malaria. *Genes Immun.* 2002;3:286–91. <https://doi.org/10.1038/sj.gene.6363877>.
- Neghina R, Iacobiciu I, Neghina AM, Marincu I. Malaria, a journey in time: in search of the Lost Myths and Forgotten Stories. *Am J Med Sci.* 2010;340: 492–8. <https://doi.org/10.1097/MAJ.0b013e3181e7fe6c>.
- World Health Organization. World Malaria Day report. Geneva: WHO; 2017.
- Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, et al. Indicators of Life-threatening malaria in African children. *N Engl J Med.* 1995;332:1399–404. <https://doi.org/10.1056/NEJM199505253322102>.
- Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN. Heritability of malaria in Africa. *PLoS Med.* 2005;253–1259. <https://doi.org/10.1371/journal.pmed.0020340>.

8. Teo Y-Y, Small KS, Kwiatkowski DP. Methodological challenges of genome-wide association analysis in Africa. *Nat Rev Genet.* 2010;11:149–60. <https://doi.org/10.1038/nrg2731>.
9. Band G, Le QS, Jostins L, Pirinen M, Kivinen K, Jallow M, et al. Imputation-Based Meta-Analysis of Severe Malaria in Three African Populations. *PLoS Genet.* 2013;9. <https://doi.org/10.1371/journal.pgen.1003509>.
10. Jallow M, Teo YY, Small KS, Rockett KA, Clark TG, Kivinen K, et al. Genomewide and fine-resolution association analysis of malaria in West Africa. *Nat Genet.* 2010;41:657–65. <https://doi.org/10.1038/ng.388>.
11. Timmann C, Thye T, Vens M, Evans J, May J, Ehmen C, et al. Genome-wide association study indicates two novel resistance loci for severe malaria. *Nature.* 2012;489. <https://doi.org/10.1038/nature11334>.
12. Band G, Rockett KA, Spencer CCA, Kwiatkowski DP, Band G, Si Le Q, et al. A novel locus of resistance to severe malaria in a region of ancient balancing selection. *Nature.* 2015;526:253–7. <https://doi.org/10.1038/nature15390>.
13. Ravenhall M, Campino S, Sepu N, Nadjm B, Mtove G, Wangai H, et al. Novel genetic polymorphisms associated with severe malaria and under selective pressure in North-eastern Tanzania. *PLoS Genet.* 2018;14:15. <https://doi.org/10.1371/journal.pgen.1007172>.
14. World Health Organization. Severe Malaria. *Tropical Med and Int Health.* 2014;19:7–131. <https://doi.org/10.1111/tmi.12313>.
15. Malaria Genomic Epidemiology Network. Reappraisal of known malaria resistance loci in a large multicenter study. *Nat Genet.* 2014;46:1197–204. <https://doi.org/10.1038/ng.3107>.
16. Verra F, Mangano VD, Modiano D. Genetics of susceptibility to *Plasmodium falciparum*: From classical malaria resistance genes towards genome-wide association studies. *Parasite Immunol.* 2009;31:234–53. <https://doi.org/10.1111/j.1365-3024.2009.01106.x>.
17. Hedrick P. Population genetics of malaria resistance in humans. *Heredity (Edinb).* 2011;107:16:283–304. <https://doi.org/10.1038/hdy.2011.16>.
18. Flori L, Sawadogo S, Esnault C, Fre N, Fumoux F, Rihet P. Linkage of mild malaria to the major histocompatibility complex in families living in Burkina Faso. *Hum Mol Genet.* 2003;12:375–8. <https://doi.org/10.1093/hmg/ddg033>.
19. Rihet P, Traoré Y, Abel L, Aucan C, Traoré-Leroux T, Fumoux F. Malaria in humans: *Plasmodium falciparum* blood infection levels are linked to chromosome 5q31–q33. *Am J Hum Genet.* 1998;63:498–505. <https://doi.org/10.1086/301967>.
20. Achidi EA, Agbenyega T, Allen S, Amodu O, Bojang K, Conway D, et al. A global network for investigating the genomic epidemiology of malaria. *Nature.* 2008;456:732–7. <https://doi.org/10.1038/nature07632>.
21. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorf LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. *Nature.* 2009;461:747–53. <https://doi.org/10.1038/nature08494>.
22. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS Discovery: biology, function, and translation. *Am J Hum Genet.* 2017;101:5–22. <https://doi.org/10.1016/j.ajhg.2017.06.005>.
23. Chimusa ER, Mbiyavanga M, Mazandu GK, Mulder NJ. AncGWAS: A post genome-wide association study method for interaction, pathway and ancestry analysis in homogeneous and admixed populations. *Bioinformatics.* 2015;32:549–56. <https://doi.org/10.1093/bioinformatics/btv619>.
24. Yang J, Zaitlen NA, Goddard ME, Visscher PM, Price AL. Advantages and pitfalls in the application of mixed model association methods. *Nat Genet.* 2014;46:100–6. <https://doi.org/10.1038/ng.2876>.
25. Daya M, Der Merwe L, Galal U, Möller M, Salie M, Chimusa ER, et al. A panel of ancestry informative markers for the complex five-way admixed South African Coloured population. *PLoS One.* 2013;8. <https://doi.org/10.1371/journal.pone.0082224>.
26. Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. *Annu Rev Genomics Hum Genet.* 2008;9:403–33. <https://doi.org/10.1146/annurev.genom.9.081307.164258>.
27. Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, et al. The African genome variation project shapes medical genetics in Africa. *Nature.* 2015;515(51):327–32. <https://doi.org/10.1038/nature13997>.
28. Slatkin M. Linkage disequilibrium - understanding the evolutionary past and mapping the medical future. *Nat Rev Genet.* 2008;9:477–85. <https://doi.org/10.1038/nrg2361>.
29. Conrad DF, Jakobsson M, Coop G, Wen X, Wall JD, Rosenberg NA, et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. *Nat Genet.* 2006;38:1251–60. <https://doi.org/10.1038/ng1911>.
30. The International HapMap 3 Consortium. Integrating common and rare genetic variation in diverse human populations. *Nature.* 2010;467:52–8. <https://doi.org/10.1038/nature09298>.
31. The 1000 Genomes Project Consortium. A map of human genome variation from population scale sequencing. *Nature.* 2011;467:1061–73.
32. Johnston HR, Hu YJ, Gao J, O'Connor TD, Abecasis GR, Wojcik GL, et al. Identifying tagging SNPs for African specific genetic variation from the African Diaspora Genome. *Sci Rep.* 2017;7:1–9. <https://doi.org/10.1038/srep46398>.
33. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. *Genet Epidemiol.* 2008;32:381–5. <https://doi.org/10.1002/gepi.20303>.
34. Popejoy A, Fullerton S. Genomics is failing on diversity. *Nature.* 2016;538:161–4. <https://doi.org/10.1038/538161a>.
35. Hormozdiari F, Zhu A, Kichaev G, Ju CJT, Segrè AV, Joo JWJ, et al. Widespread Allelic Heterogeneity in Complex Traits. *Am J Hum Genet.* 2017;100:789–802.
36. Baudure F. Red cell polymorphisms and malaria: an evolutionary approach. *Bull Mem Soc Anthropol Paris.* 2013;25:55–64.
37. Hardison R, David CHK, Belinda G, Cathy R, George P, Patrinos GP, Nicholas A, et al. HbVar: A relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. *Hum Mutat.* 2002;19:225–33.
38. Piel FB, Howes RE, Patil AP, Nyangiri OA, Gething PW, Bhatt S, et al. The distribution of haemoglobin C and its prevalence in newborns in Africa. *Sci Rep.* 2013;3:1–8. <https://doi.org/10.1038/srep01671>.
39. Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. *Eur J Hum Genet.* 2009;17:1080–5. <https://doi.org/10.1038/ejhg.2009.8>.
40. Schork NJ, Murray SS, Frazer KA, Topol EJ. Common vs. Rare Allele Hypotheses for complex diseases. *Curr Opin Genet Dev.* 2010;19:212–9. <https://doi.org/10.1016/j.gde.2009.04.010>.
41. Zuk O, Hechter E, Sunyaev SR, Lander ES. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proc Natl Acad Sci.* 2012;109:1193–8. <https://doi.org/10.1073/pnas.1119675109>.
42. Hall MD, Ebert D. The genetics of infectious disease susceptibility: Has the evidence for epistasis been overestimated? *BMC Biol.* 2013;11. <https://doi.org/10.1186/1741-7007-11-79>.
43. Karlsson EK, Kwiatkowski DP, Sabeti PC. Natural selection and infectious disease in human populations. *Nat Rev Genet.* 2014;15:379–93. <https://doi.org/10.1038/nrg3734>.
44. Wilfert L, Schmid-Hempel P. The genetic architecture of susceptibility to parasites. *BMC Evol Biol.* 2008;8:1–8. <https://doi.org/10.1186/1471-2148-8-187>.
45. Mitchell-Olds T, Willis JH, Goldstein DB. Which evolutionary processes influence natural genetic variation for phenotypic traits? *Nat Rev Genet.* 2007;8:845–56. <https://doi.org/10.1038/nrg2207>.
46. Bedu-Addo G, Meese S, Mockenhaupt FP. An ATP2B4 polymorphism protects against malaria in pregnancy. *J Infect Dis.* 2013;207:1600–3. <https://doi.org/10.1093/infdis/jit070>.
47. Li J, Glessner JT, Zhang H, Hou C, Wei Z, Bradfield JP, et al. GWAS of blood cell traits identifies novel associated loci and epistatic interactions in caucasian and African-American children. *Hum Mol Genet.* 2013;22:1457–64. <https://doi.org/10.1093/hmg/ddt534>.
48. Guerini D, Pan B, Carafoli E. Expression, purification, and characterization of isoform 1 of the plasma membrane Ca²⁺ pump. Focus on calpain sensitivity. *J Biol Chem.* 2003;278:38141–8. <https://doi.org/10.1074/jbc.M302400200>.
49. Zámbo B, Várady G, Padányi R, Szabó E, Németh A, Langó T, et al. Decreased calcium pump expression in human erythrocytes is connected to a minor haplotype in the ATP2B4 gene. *Cell Calcium.* 2017;65:73–9. <https://doi.org/10.1016/j.ceca.2017.02.001>.
50. Lessard S, Gatof ES, Beaudoin M, Schupp PG, Sher F, Ali A, et al. An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. *J Clin Invest.* 2017;127:3065–74. <https://doi.org/10.1172/JCI94378>.
51. Tiffert T, Lew VL, Ginsburg H, Krugliak M, Croisille L, Mohandas N. The hydration state of human red blood cells and their susceptibility to invasion by *Plasmodium falciparum*. *Blood.* 2005;105:4853–60. <https://doi.org/10.1182/blood-2004-12-4948>.
52. Gazarini ML, Thomas AP, Pozzan T, Garcia CRS. Calcium signaling in a low calcium environment: How the intracellular malaria parasite solves the problem. *J Cell Biol.* 2003;161:103–10. <https://doi.org/10.1083/jcb.200212130>.

53. Leffler EM, Band G, Busby GBJ, Kivinen K, Le QS, Clarke GM, et al. Resistance to malaria through structural variation of red blood cell invasion receptors. *Science*. 2017;356:1140–52. <https://doi.org/10.1126/science.aam6393>.
54. Manjurano A, Sepulveda N, Nadjm B, Mtove G, Wangai H, Maxwell C, et al. USP38, FREM3, SDC1, DDC, and LOC727982 Gene Polymorphisms and Differential Susceptibility to Severe Malaria in Tanzania. *J Infect Dis*. 2015; 212:1129–39. <https://doi.org/10.1093/infdis/jiv192>.
55. Ko WY, Kaercher KA, Giombini E, Marcatili P, Froment A, Ibrahim M, et al. Effects of natural selection and gene conversion on the evolution of human glycoporphins coding for MNS blood polymorphisms in malaria-endemic African populations. *Am J Hum Genet*. 2011;88:741–54. <https://doi.org/10.1016/j.ajhg.2011.05.005>.
56. Mayer DCG, Cofie J, Jiang L, Hartl DL, Tracy E, Kabat J, et al. Glycophorin B is the erythrocyte receptor of *Plasmodium falciparum* erythrocyte-binding ligand, EBL-1. *Proc Natl Acad Sci*. 2009;106:5348–52. <https://doi.org/10.1073/pnas.0900878106>.
57. Wang HY, Tang H, Shen CK, Wu Cl. Rapidly evolving genes in human. I. The glycoporphins and their possible role in evading malaria parasites. *Mol Biol Evol*. 2003;20:1795–804. <https://doi.org/10.1093/molbev/msg185>.
58. Leary SC. Redox regulation of SCO protein function: controlling copper at a mitochondrial crossroad. *Antioxid Redox Signal*. 2010;13:1403–16. <https://doi.org/10.1089/ars.2010.3116>.
59. Valnot I, Osmond S, Gigarel N, Mehaye B, Amiel J, Cormier-Daire V, et al. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. *Am J Hum Genet*. 2000;67:1104–9. [https://doi.org/10.1016/S0002-9297\(07\)62940-1](https://doi.org/10.1016/S0002-9297(07)62940-1).
60. Miller LH, Baruch DI, Marsh K, Doumbo OK. The pathogenic basis of malaria. *Nature*. 2002;415:673–9. <https://doi.org/10.1038/415673a>.
61. Martelle SE, Raffield LM, Palmer ND, Cox AJ, Freedman BI, Huggenschmidt CE, et al. Dopamine pathway gene variants may modulate cognitive performance in the DHS - Mind Study. *Brain Behav*. 2016;6:1–12.
62. Zhou Z, Yang J, Wang L, Zhang H, Gao Y, Shi X, et al. A dopa decarboxylase modulating the immune response of scallop chlamyri farreri. *PLoS One*. 2011;6:e18596.
63. Menge DM, Zhong D, Guda T, Gouagna L, Githure J, Beier J, et al. Quantitative trait loci controlling refractoriness to *Plasmodium falciparum* in natural *Anopheles gambiae* mosquitoes from a malaria-endemic region in western Kenya. *Genetics*. 2006;173:235–41.
64. Steed E, Rodrigues NTL, Balda MS, Matter K. Identification of MarvelD3 as a tight junction-associated transmembrane protein of the occludin family. *BMC Cell Biol*. 2009;10:1–14.
65. Huang D, Cancilla MR, Morahan G. Complete primary structure, chromosomal localisation, and definition of polymorphisms of the gene encoding the human interleukin-12 p40 subunit. *Genes Immun*. 2000;1:515–20.
66. Luty AJF, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, et al. Low interleukin-12 activity in severe *Plasmodium falciparum* malaria. *Infect Immun*. 2000;68:3909–15.
67. Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: A key cytokine in inflammatory diseases. *Ann Med*. 2011;43:503–11.
68. Minke B, Wu C-F, Pak W. Genes required for cytotoxicity against virus-infected target cells in *K* and *D* regions of H-2 complex. *Nature*. 1975; 254:84–7.
69. Hill AV, Allsopp CE, Kwiatkowski D, Anstey NM, Twumasi P, Rowe PA, Benett S, Brewster D, McMichael AJ, Greenwood BM. Common west African HLA antigens are associated with protection from severe malaria. *Nature*. 1991;351:595–600.
70. Dudbridge F. Polygenic Epidemiology. *Genet Epidemiol*. 2016;40:268–72.
71. Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. Common SNPs explain a large proportion of the heritability for human height. *Nat Genet*. 2010;42:565–9.
72. International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460: 748–52.
73. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: A tool for genome-wide complex trait analysis. *Am J Hum Genet*. 2011;88:76–82. <https://doi.org/10.1016/j.ajhg.2010.11.011>.
74. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: A Tool Set for whole-genome association and population-based linkage Analyses. *Am J Hum Genet*. 2007;81:559–75. <https://doi.org/10.1086/519795>.
75. Loh P, Tucker G, Bulik-sullivan BK, Vilhjálmsson BJ, Finucane HK, Salem RM, et al. Efficient Bayesian mixed-model analysis increases association power in large cohorts; 2015. <https://doi.org/10.1038/ng.3190>.
76. Erbe M, Hayes BJ, Matukumalli LK, Goswami S, Bowman PJ, Reich CM, et al. Erratum to "Improving accuracy of genomic predictions within and between dairy cattle breeds with imputed high-density single nucleotide polymorphism panels" (*J. Dairy Sci.* 95:4114–4129). *J Dairy Sci*. 2014;97:6622. <https://doi.org/10.3168/jds.2014-97-10-6622>.
77. Speed D, Hemani G, Johnson MR, Balding DJ. Improved heritability estimation from genome-wide SNPs. *Am J Hum Genet*. 2012;91:1011–21. <https://doi.org/10.1016/j.ajhg.2012.10.010>.
78. Speed D, Cai N, Johnson MR, Nejentsev S, Balding DJ. Reevaluation of SNP heritability in complex human traits. *Nat Genet*. 2017;49:986–92.
79. Golan D, Lander ES, Rosset S. Measuring missing heritability: Inferring the contribution of common variants. *Proc Natl Acad Sci*. 2014;111:E5272–81. <https://doi.org/10.1073/pnas.1419064111>.
80. Bulik-sullivan BK, Loh P, Finucane HK, Ripke S, Yang J, Working S, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47:1–7. <https://doi.org/10.1038/ng.3211>.
81. Frank SA. Recognition and Polymorphism in host-parasite genetics. *Philos Trans Biol Sci*. 1994;346:283–93. <https://doi.org/10.1098/rstb.1994.0145>.
82. Tian C, Hromatka BS, Kiefer AK, Eriksson N, Noble SM, Tung JY, et al. Genome-wide association and HLA region fine-mapping studies identify susceptibility loci for multiple common infections. *Nat Commun*. 2017;8. <https://doi.org/10.1038/s41467-017-00257-5>.
83. Wei W-H, Hemani G, Haley CS. Detecting epistasis in human complex traits. *Nature Rev Genet*. 2014;15:722–33. <https://doi.org/10.1038/nrg3747>.
84. Cordell HG. Detecting gene-gene interactions that underlie human diseases. *Nat Rev Genet*. 2009;10:392–404.
85. Castillejo-López C, Delgado-Vega AM, Wojcik J, Kozlyev SV, Thavathiru E, Wu YY, et al. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. *Ann Rheum Dis*. 2012;71:136–42.
86. Evans DM, Spencer CCA, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet*. 2011;43:761–7.
87. Strange A, Capon F, Spencer CCA, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. *Nat Genet*. 2010;42:985–90.
88. Williams TN, Mwangi TW, Wambua S, Peto TEA, Weatherall DJ, Gupta S, et al. Negative epistasis between the malaria-protective effects of α + β thalassaemia and the sickle cell trait. *Nature Genet*. 2005;37:1253–7.
89. Atkinson SH, Uyoga SM, Nyatichi E, Macharia AW, Nyutu G, Ndila C, et al. Epistasis between the haptoglobin common variant and α + thalassaemia influences risk of severe malaria in Kenyan children. *Blood*. 2014;123:2008–16.
90. Opi DH, Swann O, Macharia A, Uyoga S, Band G, Ndila CM, et al. Two complement receptor one alleles have opposing associations with cerebral malaria and interact with α -thalassaemia. *Elife*. 2018;7:1–27.
91. van der Sijde MR, Ng A, Fu J. Systems genetics: From GWAS to disease pathways. *Biochim Biophys Acta - Mol Basis Dis*. 1842;2014:1903–9. <https://doi.org/10.1016/j.bbadis.2014.04.025>.
92. Boyle EA, Li Yi, Pritchard JK. Leading Edge Perspective An Expanded View of Complex Traits. *Cell*. 2017;169:1177–86.
93. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic Localization of Common. *Science* (80-). 2012;337:1190–5.
94. Spain SL, Barrett JC. Strategies for fine-mapping complex traits. *Hum Mol Genet*. 2015;24:111–9.
95. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, Shi Y, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. *Nat Genet*. 2011; 43:55–9. <https://doi.org/10.1038/ng.732>.
96. Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal variants by statistical fine-mapping. *Nat Rev Genet*. 2018;19:491–504.
97. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. *Nat Genet*. 2010;42:1049–51.
98. Farh KKH, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature*. 2015;518:337–43.
99. Vaughan AM, Aly AS, Kappe SHI. Malaria parasite pre-erythrocytic stage infection: Gliding and Hiding. *Cell Host Microbe*. 2008;4:209–18.

100. Wang L, Zhang B, Wolfinger RD, Chen X. An integrated approach for the analysis of biological pathways using mixed models. *PLoS Genet.* 2008;4:e1000115.
101. Zeggini E, Ioannidis JPA. Meta-analysis in genome-wide association studies. *Pharmacogenomics.* 2009;10:191–201.
102. Liu C, Bousman CA, Pantelis C, Skafidas E, Zhang D, Yue W, et al. Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations. *Transl Psychiatry.* 2017;7:e1037.
103. O'Dushlaine C, Kenny E, Heron E, Donohoe G, Gill M, Morris DW, et al. Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. *Mol Psychiatry.* 2011;16:286–92.
104. Kao PYP, Leung KH, Chan LWC, Yip SP, Yap MKH. Pathway analysis of complex diseases for GWAS, extending to consider rare variants, multi-omics and interactions. *Biochim Biophys Acta - Gen Subj.* 1861;2017:335–53.
105. Xu J, Zhao L, Liu D, Hu S, Song X, Li J, et al. EWAS: epigenome-wide association study software 2.0. *Bioinformatics.* 2018;34:2657–8.
106. Gupta H, Chaudhari S, Rai A, Bhat S, Sahu PK, Hande MH, et al. Genetic and epigenetic changes in host ABCB1 influences malaria susceptibility to *Plasmodium falciparum*. *PLoS One.* 2017;12:e0175702.
107. Quin JE, Bujila I, Chérif M, Sanou GS, Qu Y, Homann MV, et al. Major transcriptional changes observed in the Fulani, an ethnic group less susceptible to malaria. *Elife.* 2017;6:1–19.
108. Arama C, Quin JE, Kouriba B, Farrants AKÓ, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. *Front Immunol.* 2018;9:1–8.
109. James F. Epigenome-Wide Association Studies (EWAS): Past, Present, and Future 2015. *Methods Mol Biol.* 2015;1238:51–63.
110. Griffiths MJ, Shafi MJ, Popper SJ, Hemingway CA, Kortok MM, Wathen A, et al. Genomewide analysis of the host response to malaria in Kenyan children. *J Infect Dis.* 2005;191:1599–611.
111. Lamonte G, Philip N, Reardon J, Lacsina JR, Chapman L, Thornburg CD, et al. Translocation of sickle cell erythrocyte microRNAs into *Plasmodium falciparum* inhibits parasite translation and contributes to malaria resistance. *Cell Host Microbe.* 2012;12(2):187–99. <https://doi.org/10.1016/j.chom.2012.06.007>.
112. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. *Genome Biol.* 2017;18:1–15.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

